These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 7755503)
21. Vaccination as a modality to prevent Lyme disease. A status report. Wormser GP Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796 [TBL] [Abstract][Full Text] [Related]
22. Artificial-infection protocols allow immunodetection of novel Borrelia burgdorferi antigens suitable as vaccine candidates against Lyme disease. Wallich R; Jahraus O; Stehle T; Tran TT; Brenner C; Hofmann H; Gern L; Simon MM Eur J Immunol; 2003 Mar; 33(3):708-19. PubMed ID: 12616491 [TBL] [Abstract][Full Text] [Related]
23. Detection of Lyme disease after OspA vaccine. Schutzer SE; Luan J; Coyle PK N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653 [No Abstract] [Full Text] [Related]
24. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype. Schaible UE; Wallich R; Kramer MD; Gern L; Anderson JF; Museteanu C; Simon MM Vaccine; 1993; 11(10):1049-54. PubMed ID: 8212826 [TBL] [Abstract][Full Text] [Related]
25. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis. Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431 [TBL] [Abstract][Full Text] [Related]
26. Epitopes on the outer surface protein A of Borrelia burgdorferi recognized by antibodies and T cells of patients with Lyme disease. Shanafelt MC; Anzola J; Soderberg C; Yssel H; Turck CW; Peltz G J Immunol; 1992 Jan; 148(1):218-24. PubMed ID: 1370170 [TBL] [Abstract][Full Text] [Related]
27. Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters. Lovrich SD; Jobe DA; Schell RF; Callister SM Clin Diagn Lab Immunol; 2005 Jun; 12(6):746-51. PubMed ID: 15939749 [TBL] [Abstract][Full Text] [Related]
28. A mouse model for Borrelia burgdorferi infection: pathogenesis, immune response and protection. Schaible UE; Wallich R; Kramer MD; Museteanu C; Simon MM Behring Inst Mitt; 1991 Feb; (88):59-67. PubMed ID: 2049047 [TBL] [Abstract][Full Text] [Related]
29. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378 [TBL] [Abstract][Full Text] [Related]
30. Detection of Borrelia burgdorferi-specific CD8+ cytotoxic T cells in patients with Lyme arthritis. Busch DH; Jassoy C; Brinckmann U; Girschick H; Huppertz HI J Immunol; 1996 Oct; 157(8):3534-41. PubMed ID: 8871653 [TBL] [Abstract][Full Text] [Related]
31. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi. Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011 [TBL] [Abstract][Full Text] [Related]
32. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B. Fikrig E; Tao H; Chen M; Barthold SW; Flavell RA J Clin Invest; 1995 Oct; 96(4):1706-14. PubMed ID: 7560061 [TBL] [Abstract][Full Text] [Related]
33. Vaccination against lyme disease with recombinant Borrelia burgdorferi outer-surface protein A (rOspA) in horses. Chang Y; Novosol V; McDonough SP; Chang CF; Jacobson RH; Divers T; Quimby FW; Shin S; Lein DH Vaccine; 1999 Oct; 18(5-6):540-8. PubMed ID: 10519945 [TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697 [TBL] [Abstract][Full Text] [Related]
35. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Probert WS; LeFebvre RB Infect Immun; 1994 May; 62(5):1920-6. PubMed ID: 8168958 [TBL] [Abstract][Full Text] [Related]
36. Long-term protection of mice from Lyme disease by vaccination with OspA. Fikrig E; Barthold SW; Kantor FS; Flavell RA Infect Immun; 1992 Mar; 60(3):773-7. PubMed ID: 1541551 [TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. Schoen RT; Meurice F; Brunet CM; Cretella S; Krause DS; Craft JE; Fikrig E J Infect Dis; 1995 Nov; 172(5):1324-9. PubMed ID: 7594671 [TBL] [Abstract][Full Text] [Related]
38. Prospects for a vaccine to prevent Lyme disease in humans. Wormser GP Clin Infect Dis; 1995 Nov; 21(5):1267-74. PubMed ID: 8589153 [TBL] [Abstract][Full Text] [Related]